A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Summary

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Timeline

Start

2026-03-04

Primary completion

2028-04-30

Completion

2028-04-30

Drugs

Indications